

## Supplementary Material

### **A New Synthesis of 4,5,6,7-Tetrahydropyrazolo[1,5-*c*]pyrimidines by a Retro-Mannich Cascade Rearrangement**

*Raffaele Colombo,<sup>A</sup> Kyu Ok Jeon,<sup>A</sup> Donna M. Huryn,<sup>A</sup> Matthew G. LaPorte,<sup>A</sup> and Peter Wipf<sup>A,B</sup>*

<sup>A</sup> Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, USA.

<sup>B</sup> Corresponding author. Email: pwipf@pitt.edu


### General Procedure 1

Sodium triacetoxyborohydride (167 mg, 0.788 mmol), the selected amine (0.439 mmol) and acetic acid (23.0  $\mu$ L, 0.402 mmol) were added to a solution of aldehyde **44** (100 mg, 0.394 mmol) in DCE (15.0 mL). The reaction mixture was stirred at rt for 3 h, quenched with saturated NaHCO<sub>3</sub> solution and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3x). The organic phases were combined, washed with brine, dried (MgSO<sub>4</sub>), and concentrated. The crude residue was purified by chromatography on SiO<sub>2</sub> or basic alumina (*vide infra*) to afford the desired product.

### General Procedure 2

To a solution of carboxylate salt **52** (90.0 mg, 0.342 mmol) in DMF (3.0 mL) was added HATU (260 mg, 0.684 mmol), *N,N*-diisopropylethylamine (240  $\mu$ L, 1.38 mmol) and the selected amine (0.418 mmol). The reaction mixture was stirred at rt for 24 h, diluted with EtOAc (20 mL) and washed with water and brine. The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The crude was purified by chromatography to afford the desired product.

1-Benzyl-3-methylpiperidin-4-one **28**,<sup>[1]</sup> 9-benzyl-9-azabicyclo[3.3.1]nonan-3-one **30**,<sup>[2]</sup> 1-benzyl-2,3-dihydroquinolin-4(1*H*)-one **32**,<sup>[3]</sup> and 1-benzylazepan-4-one **39**,<sup>[4]</sup> and were prepared according to literature procedures.



*Ethyl 6-benzyl-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidine-2-carboxylate 11, ethyl 5-benzyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-3-carboxylate 8, ethyl 5-(2-(benzylamino)ethyl)-1H-pyrazole-3-carboxylate 16*

Sodium (0.11 g, 4.7 mmol) was added to ice-cooled EtOH (15 mL) under a nitrogen atmosphere. After 2 h, the solution was cooled to -10 °C and diethyl oxalate (0.59 mL, 4.3 mmol) was added dropwise. *N*-Benzyl-piperidinone (0.80 mL, 4.3 mmol) was added dropwise within an hour. The mixture was warmed to rt and stirred for 10 h. The hydrazine monohydrate (0.23 mL, 4.7 mmol) was added and the mixture was stirred for 5 min. Then, pyridinium *p*-toluenesulfonate (PPTS) (2.2 g, 8.6 mmol, 2 equiv) was added and the mixture was stirred for 5-6 h at rt. The reaction was monitored by LC-MS (gradient of 92% water/0.1% formic acid, 3% acetonitrile/0.1% formic acid/5% MeOH to 2% water/0.1% formic acid, 93% acetonitrile/0.1% formic acid, 5% MeOH). The reaction mixture was diluted with sat. NaHCO<sub>3</sub> (100 mL) and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The crude residue was purified by chromatography on SiO<sub>2</sub> (solid load, EtOAc:hexanes, 1:1, then EtOAc, and finally EtOAc:MeOH, 4:1) to give ethyl 6-benzyl-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidine-2-carboxylate **11** (0.77 g, 2.7 mmol, 62%), ethyl 5-benzyl-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-c]pyridine-3-carboxylate **8** (0.17 g, 0.60 mmol, 14%) and ethyl 5-(2-(benzylamino)ethyl)-1*H*-pyrazole-3-carboxylate **16** (0.12 g, 0.44 mmol, 10%) as viscous oils.

**11**: IR 2982, 2924, 1711, 1452, 1221, 1191, 1094, 1023, 775, 734 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  7.33-7.27 (m, 5 H), 6.60 (s, 1 H), 4.92 (s, 2 H), 4.38 (q, *J* = 7.1 Hz, 2 H), 3.79 (s, 2 H), 3.10 (t, *J* = 6.1 Hz, 2 H), 2.92 (t, *J* = 6.1 Hz, 2 H), 1.38 (t, *J* = 7.1 Hz, 3 H); <sup>13</sup>C NMR (126 MHz; CDCl<sub>3</sub>)  $\delta$  162.6, 142.9, 138.0, 136.9, 128.7, 128.5, 127.6, 106.1, 68.7, 60.8, 56.3, 46.3, 19.7, 14.3; HRMS (ESI) *m/z* calcd for C<sub>16</sub>H<sub>20</sub>O<sub>2</sub>N<sub>3</sub> (M+H)<sup>+</sup> 286.1550, found 286.1540.

**8**: IR 3147, 2983, 2931, 1712, 1451, 1245, 1324, 1245, 1145, 1044, 727 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.41-7.29 (m, 5 H), 4.35 (q, *J* = 7.1 Hz, 2 H), 3.77 (s, 4 H), 2.81-2.80 (m, 4 H), 1.34 (t, *J* = 7.1 Hz, 3 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  161.4, 143.9, 138.2, 134.1, 129.1, 128.5, 127.2, 118.2, 61.9, 60.8, 49.7, 49.4, 22.7, 14.3; HRMS (ESI) *m/z* calcd for C<sub>16</sub>H<sub>20</sub>O<sub>2</sub>N<sub>3</sub> (M+H)<sup>+</sup> 286.1550, found 286.1543.

<sup>[1]</sup> D. Burdi, K. L. Spear, L. W. Hardy, *WO2010/114971*, **2010**

<sup>[2]</sup> R. H. Mach, R. R. Luedtke, C. D. Unsworth, V. A. Boundy, P. A. Nowak, J. G. Scripko, S. T. Elder, J. R. Jackson, P. L. Hoffman, P. H. Evora, A. V. Rae, P. B. Molinoff, S. R. Childers, R. L. Ehrenkaufert, *J. Med. Chem.* **1993**, *36*, 3707-3720. doi:10.1021/jm00075a028


<sup>[3]</sup> (a) H. B. Josien, J. W. Clader, W. J. Greenlee, M. J. Mayer, R. J. Herr, J. L. Davis, K. Deng, M. M Hsia, S. Wan, *WO2010/085525*, **2010**; (b) E. K. Bayburt, J. F. Daanen, A. R. Gomtsyan, S. P. Latshaw, C. H. Lee, R. G. Schmidt, *US patent 2008153871* **2008**

<sup>[4]</sup> Adapted from Y. S. Huang, W. Q. Zhang; P. F. Zhang, X. G. Liu, *Ind. Eng. Chem. Res.*, **2010**, *49*, 12164-12167. doi:10.1021/ie101807g

**16**: IR 3203, 3083, 2975, 2844, 1715, 1450, 1420, 1301, 1226, 1159, 1107  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.34-7.25 (m, 5H), 6.58 (s, 1H), 4.37 (q,  $J = 7.1$  Hz, 2H), 3.85 (s, 2H), 2.99 (t,  $J = 6.3$  Hz, 2H), 2.88 (t,  $J = 6.3$  Hz, 2H), 1.38 (t,  $J = 7.1$  Hz, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  162.0, 145.3, 141.9, 138.9, 128.5, 128.2, 127.2, 106.3, 60.7, 53.4, 47.8, 25.7, 14.2; HRMS (ESI)  $m/z$  calcd for  $\text{C}_{15}\text{H}_{20}\text{O}_2\text{N}_3$  ( $\text{M}+\text{H}$ ) $^+$  274.1550, found 274.1548.


#### Reaction Optimization:

Sodium (0.109 g, 4.74 mmol) was added to ice-cooled EtOH (15 mL) under a nitrogen atmosphere. After 2 h, the solution was further cooled to  $-10$   $^\circ\text{C}$  and diethyl oxalate (0.591 mL, 4.32 mmol) was added dropwise. *N*-benzyl-piperidinone **10** (0.8 mL, 4.32 mmol) was added dropwise within an hour. The mixture was warmed to rt and stirred for 10 h. The hydrazine monohydrate (0.234 mL, 4.75 mmol) was added and the mixture was stirred for 5 min. Then, the selected acid (see Table 1) was added and the mixture was stirred for 5-6 h at rt. The reaction was monitored by HPLC-MS. The reaction mixture was diluted with sat.  $\text{NaHCO}_3$  (100 mL) and extracted with EtOAc (3x). The organic phases were combined, washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ), concentrated. The crude residue was purified by chromatography on  $\text{SiO}_2$  (solid load, EtOAc:hexanes, 1:1, then EtOAc, and finally EtOAc:MeOH, 4:1) to give ethyl 6-benzyl-4,5,6,7-tetrahydropyrazolo[1,5-*c*]pyrimidine-2-carboxylate **11**, ethyl 5-benzyl-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridine-3-carboxylate **8** and ethyl 5-(2-(benzylamino)ethyl)-1*H*-pyrazole-3-carboxylate **16** as viscous oils. See Table 1 in the manuscript for the isolated yields.



#### Ethyl 6-benzyl-4-methyl-4,5,6,7-tetrahydropyrazolo[1,5-*c*]pyrimidine-2-carboxylate **29**


Sodium (0.045 g, 1.9 mmol) was added to ice-cooled EtOH (10 mL) under a nitrogen atmosphere. After 2 h, the solution was cooled to  $-10$   $^\circ\text{C}$  and diethyl oxalate (0.24 mL, 1.8 mmol) was added dropwise. A solution of 1-benzyl-3-methylpiperidin-4-one **28** (0.36 g, 1.8 mmol) in EtOH (1 mL) was added dropwise within an hour. The mixture was warmed to rt and stirred for 10 h. Hydrazine monohydrate (0.10 mL, 2.0 mmol) and after 5 min acetic acid (0.13 mL, 2.2 mmol) were added. The reaction mixture was stirred for 3 h at rt, diluted with sat.  $\text{NaHCO}_3$  (20 mL) and extracted EtOAc (3x). The organic phases were combined, washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ), and concentrated. The crude residue was purified by chromatography on  $\text{SiO}_2$  (solid load, EtOAc:hexanes, 7:3) to afford the desired product **29** as a clear colorless oil (0.20 g, 37%): IR (film) 2975, 2805, 1711, 1452, 1379, 1363, 1327, 1217, 1193, 1107, 775, 740  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.33-7.26 (m, 5 H), 6.65 (s, 1 H), 4.86 (q,  $J_{AB} = 11.4$  Hz, 2 H), 4.38 (q,  $J = 7.1$  Hz, 2 H), 3.79 (s, 2 H), 3.26-3.17 (m, 1 H), 3.12 (dd,  $J = 12.8, 5.8$  Hz, 1 H), 2.59 (dd,  $J = 12.5, 10.3$  Hz, 1 H), 1.38 (t,  $J = 7.1$  Hz, 3 H), 1.24 (d,  $J = 6.8$  Hz, 3 H);  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  162.6, 144.1, 143.0, 136.9, 128.7, 128.5, 127.6, 105.3, 68.7, 60.8, 57.1, 54.7, 26.1, 17.7, 14.3; HRMS (ESI)  $m/z$  calcd for  $\text{C}_{17}\text{H}_{22}\text{O}_2\text{N}_3$  ( $\text{M}+\text{H}$ ) $^+$  300.1707, found 300.1695.



#### Ethyl 11-benzyl-4,5,6,7,8,9-hexahydro-5,9-epiminopyrazolo[1,5-*a*]azocine-2-carboxylate **31**


Sodium (0.055 g, 2.4 mmol) was added to ice-cooled EtOH (12 mL) under a nitrogen atmosphere. After 2 h, the solution was cooled to  $-10$   $^\circ\text{C}$  and diethyl oxalate (0.30 mL, 2.2 mmol) was added dropwise. 9-Benzyl-9-azabicyclo[3.3.1]nonan-3-one **30** (0.5 g, 2.2 mmol) was added as solid in one portion. The mixture was warmed to rt and stirred for 10 h. The hydrazine monohydrate (0.12 mL, 2.4 mmol) and after 5 min acetic acid (0.15, 2.6 mmol) were added. The reaction mixture was stirred for 3 h at rt, diluted with sat.  $\text{NaHCO}_3$  (40 mL) and extracted EtOAc (3x). The organic phases were combined, washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ), and concentrated. The crude residue was purified by chromatography on  $\text{SiO}_2$  (solid load, EtOAc:hexanes, 4:1, to 100% EtOAc) to afford **31** as a colorless oil (0.22 g, 31%): IR (film) 2946, 2883, 2845, 1715, 1432, 1242, 1193, 1108, 1025, 910, 723, 697  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.28-7.23 (m, 5 H), 6.58 (s, 1 H), 5.18 (s, 1 H), 4.39-4.38 (m, 2 H), 3.64 (q,  $J_{AB}$ , 2 H), 3.28-3.25 (m, 2 H), 2.58 (d,  $J = 15.9$  Hz, 1 H), 1.96-1.89 (m, 3 H), 1.62 (d,  $J = 13.0$  Hz, 1 H), 1.50 (d,  $J = 13.8$  Hz, 1 H), 1.38 (s, 3 H), 1.06 (q,  $J = 13.3$  Hz, 1 H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  162.7,

142.6, 138.8, 137.4, 128.4, 128.3, 127.2, 105.0, 73.0, 60.6, 56.9, 48.6, 32.1, 30.7, 22.5, 15.3, 14.2; HRMS (ESI)  $m/z$  calcd for  $C_{19}H_{24}O_2N_3$  ( $M+H$ )<sup>+</sup> 326.1863, found 326.1854.




*Ethyl 5-benzyl-5H-pyrazolo[4,3-c]quinoline-3-carboxylate 34*

Sodium (0.053 g, 2.3 mmol) was added to ice-cooled EtOH (15 mL) under a nitrogen atmosphere. After 1 h, the solution was cooled to -10 °C and diethyl oxalate (0.29 mL, 2.1 mmol) was added dropwise, then **32** (0.50 g, 2.1 mmol) was added as solid in one portion (it dissolved in 2-3 h). The mixture was warmed to rt and stirred for 10 h. The hydrazine monohydrate (0.11 mL, 2.3 mmol) and after 5 min acetic acid (0.15 mL, 2.5 mmol) were added. The mixture was stirred for 3 h at rt, then diluted with sat.  $NaHCO_3$  and extracted with EtOAc (3x). The organic phases were combined, washed with brine, dried ( $Na_2SO_4$ ), concentrated and the crude residue was purified by chromatography on  $SiO_2$  (solid load, EtOAc:hexanes, 1:4 to 1:1) to afford **33** as a yellow-orange solid, which was not air stable and spontaneously converted into a orange solid **34** (0.28 g, 40%): Mp 180-182 °C; IR (film) 3379, 3065, 2983, 2927, 1689, 1615, 1473, 1451, 1413, 1383, 1369, 1204, 1193, 1025, 999, 757, 693  $cm^{-1}$ ;  $^1H$  NMR (400 MHz, DMSO)  $\delta$  9.81 (s, 1 H), 8.81 (d,  $J = 7.2$  Hz, 1 H), 8.19 (d,  $J = 8.1$  Hz, 1 H), 7.85-7.81 (m, 2 H), 7.40-7.28 (m, 5 H), 6.27 (s, 2 H), 4.44 (q,  $J = 7.0$  Hz, 2 H), 1.41 (t,  $J = 7.1$  Hz, 3 H);  $^{13}C$  NMR (101 MHz, DMSO)  $\delta$  162.7, 149.8, 146.0, 142.7, 135.8, 133.4, 130.0, 129.5, 128.7, 127.2, 123.9, 121.1, 119.8, 116.3, 60.6, 58.8, 14.9; HRMS (ESI)  $m/z$  calcd for  $C_{20}H_{18}O_2N_3$  ( $M+H$ )<sup>+</sup> 332.1394, found 332.1389.



*Ethyl 5-benzyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-3-carboxylate 38*

Sodium (0.328 mg, 14.3 mmol) was added to ice-cooled ethanol (30 mL) under a nitrogen atmosphere. After 2 h, the solution was cooled to -10 °C and diethyl oxalate (0.183 g, 12.6 mmol) was added dropwise. 1-Benzyl-3-pyrrolidinone **35** (2 g, 11.4 mmol) was added dropwise within an hour. The mixture was warmed to rt and stirred for 10 h. The hydrazine monohydrate (1.23 mL, 12.6 mmol) and after 5 min acetic acid (2.0 mL, 34 mmol) were added. The reaction mixture was stirred for 10 h at rt, then 12 h at reflux. The HPLC-MS showed the formation of hydrazone **37**. The solvents were evaporated and the crude residue was redissolved in acetic acid (10 mL) and heated at reflux for 3h. The reaction mixture was diluted with sat.  $NaHCO_3$  (100 mL) and extracted EtOAc (3x). The organic phase were combined, washed with brine, dried ( $Na_2SO_4$ ) and concentrated. The crude black residue was purified by chromatography on  $SiO_2$  (solid load, EtOAc:hexanes, 4:6 to 7:3) to afford **38** as a brown oil (1.4 g, 50%): IR 3139, 3068, 2901, 2785, 1723, 1439, 1309, 1212, 1134, 1040, 738  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  7.41-7.25 (m, 5 H), 4.31 (q,  $J = 7.1$  Hz, 2 H), 3.99 (s, 2 H), 3.93 (t,  $J = 1.4$  Hz, 2 H), 3.88 (t,  $J = 1.4$  Hz, 2 H), 1.31 (t,  $J = 7.1$  Hz, 3 H);  $^{13}C$  NMR (101 MHz,  $CDCl_3$ )  $\delta$  159.8, 157.7, 138.5, 128.5, 128.3, 127.5, 127.1, 125.1, 61.0, 60.2, 51.5, 51.4, 14.1; HRMS (ESI)  $m/z$  calcd for  $C_{15}H_{18}O_2N_3$  ( $M+H$ )<sup>+</sup> 272.1394, found 272.1389.




*Ethyl 6-benzyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepine-3-carboxylate 41, ethyl 5-benzyl-2,4,5,6,7,8-hexahydropyrazolo[4,3-c]azepine-3-carboxylate 42, and ethyl 7-benzyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-c][1,3]diazepine-2-carboxylate 43*

Sodium (127 mg, 5.53 mmol) was added to ice-cooled ethanol (10 mL) under a nitrogen atmosphere. After 2 h, the solution was cooled to -10 °C and diethyl oxalate (0.661 mL, 4.87 mmol) was added dropwise. 1-Benzylazepan-4-one 15 (0.9 g, 4.43 mmol) was added dropwise within an hour. The mixture was warmed to room temperature and stirred for 10 h. The hydrazine monohydrate (0.239 mL, 4.87 mmol) and after 5 min acetic acid (0.768 mL, 13.3 mmol) were added. The reaction mixture was stirred for 3 h at rt. The reaction mixture was diluted with sat. NaHCO<sub>3</sub> (40 mL) and extracted with EtOAc (3x). The organic phase were combined, washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The crude residue was purified by chromatography on SiO<sub>2</sub> (solid load, EtOAc/hexanes, 4:6, to 7:3) to afford the product **43** as a oil (0.10 g, 8%), and a mixture of **41** and **42** as a oil. The mixture of **41** and **42** was further purified by chromatography on SiO<sub>2</sub> (liquid load, toluene:MeOH, 100:6) to afford **41** (0.40 g, 30%) and **42** (0.54 g, 41%), both as colorless oils.

**41**: IR (film) 3128, 2938, 2908, 2819, 1711, 1450, 1312, 1256, 1160, 1130, 731, 679; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.43-7.29 (m, 5 H), 4.38 (q, *J* = 7.1 Hz, 2 H), 3.82 (s, 2 H), 3.10-3.07 (m, 2 H), 2.97-2.95 (m, 2 H), 2.85-2.82 (m, 4 H), 1.38 (t, *J* = 7.1 Hz, 3 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 161.3, 151.3, 139.0, 133.6, 128.9, 128.3, 127.1, 123.5, 61.7, 60.9, 55.4, 54.0, 28.1, 23.8, 14.3; HRMS (ESI) *m/z* calcd for C<sub>17</sub>H<sub>22</sub>O<sub>2</sub>N<sub>3</sub> (M+H)<sup>+</sup> 300.1707, found 300.1700.


**42**: IR (film) 3285, 3151, 3106, 2920, 1708, 1447, 1309, 1253, 1171, 1052, 1022, 735, 697 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.30-7.25 (m, 5 H), 4.20 (q, *J* = 6.9 Hz, 2 H), 4.07 (s, 2 H), 3.64 (s, 2 H), 3.15 (br t, *J* = 2.5 Hz, 2 H), 2.93 (br t, *J* = 2.5 Hz, 2 H), 1.81 (s, 2 H), 1.19 (t, *J* = 6.9 Hz, 3 H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.9, 152.6, 139.0, 133.6, 128.9, 128.2, 126.9, 121.6, 60.9, 58.3, 58.2, 48.4, 27.9, 24.1, 14.0; HRMS (ESI) *m/z* calcd for C<sub>17</sub>H<sub>22</sub>O<sub>2</sub>N<sub>3</sub> (M+H)<sup>+</sup> 300.1707, found 300.1697.

**43**: IR (film) 2938, 2849, 1715, 1450, 1432, 1204, 1186, 1115, 1096, 1044, 749, 735; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.31-7.25 (m, 5 H), 6.63 (s, 1 H), 5.27 (s, 2 H), 4.40 (q, *J* = 7.1 Hz, 2 H), 3.53 (s, 2 H), 3.14 (t, *J* = 4.5 Hz, 2 H), 2.86 (t, *J* = 4.5 Hz, 2 H), 1.70 (br s, 2 H), 1.39 (t, *J* = 7.1 Hz, 3 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 162.4, 144.6, 141.4, 137.4, 128.5, 128.2, 127.0, 107.9, 71.9, 60.5, 54.3, 52.2, 25.4, 21.8, 14.2; HRMS (ESI) *m/z* calcd for C<sub>17</sub>H<sub>22</sub>O<sub>2</sub>N<sub>3</sub> (M+H)<sup>+</sup> 300.1707, found 300.1707.




#### 6-Benzyl-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidine-2-carbaldehyde **44**

At -78 °C, DIBAL-H (0.90 mL, 0.90 mmol, 1 M solution in toluene, pre cooled to -78 °C under inert atmosphere) was slowly added to a solution of **11** (0.10 mg, 0.35 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2.0 mL). The reaction mixture was stirred at -78 °C for 1 h, quenched with methanol (1.0 mL) at -78 °C and warmed to rt. The solution was diluted with aqueous 1 M HCl and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3x). The organic phases were combined, washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to afford **44** as colorless oil (78 mg, 83%): IR (thin film, CH<sub>2</sub>Cl<sub>2</sub>) 2937, 2805, 1691, 1452, 1115, 788 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.94 (s, 1 H), 7.37-7.32 (m, 5 H), 6.60 (s, 1 H), 4.94 (s, 2 H), 3.83 (s, 2 H), 3.14 (t, *J* = 6.4 Hz, 2 H), 2.96 (t, *J* = 6.4 Hz, 2 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 186.8, 150.7, 138.9, 136.8, 128.8, 128.7, 127.8, 103.2, 68.8, 56.5, 46.5, 19.9; HRMS (ESI) *m/z* calcd for C<sub>14</sub>H<sub>16</sub>N<sub>3</sub>O (M+H)<sup>+</sup> 242.1288, found 242.1289.




#### N-Benzyl-1-(6-benzyl-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidin-2-yl)methanamine **45**

Prepared according to the General Procedure 1, using benzylamine (48.0 μL, 0.439 mmol). The crude residue was purified by chromatography on SiO<sub>2</sub> (MeOH:CH<sub>2</sub>Cl<sub>2</sub>, 1:20, with 0.1% Et<sub>3</sub>N) to afford the desired product **45** (86.0 mg, 66%) as a colorless oil: IR (thin film, CH<sub>2</sub>Cl<sub>2</sub>) 3359, 3019, 2919, 1541, 1493, 1450, 1025 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.38-7.23 (m, 10 H), 6.01 (s, 1 H), 4.81 (s, 2 H), 3.86 (s, 2 H), 3.81 (s, 2 H), 3.05 (t, *J* = 6.4 Hz, 2 H), 2.88 (t, *J* = 6.4 Hz, 2 H), 1.95 (br s, 1 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 150.8, 140.2, 137.4, 137.3, 128.9, 128.5, 128.31, 128.25, 127.6, 126.9, 101.9, 68.0, 56.7, 53.4, 46.9, 46.7, 20.1; HRMS (ESI) *m/z* calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub> (M+H)<sup>+</sup> 333.2074, found 333.2078.




*N*-((6-Benzyl-4,5,6,7-tetrahydropyrazolo[1,5-*c*]pyrimidin-2-yl)methyl)cyclohexylamine **46**

Prepared according to the General Procedure 1, using cyclohexylamine (50.0  $\mu$ L, 0.436 mmol). The residue was purified by chromatography on basic  $\text{Al}_2\text{O}_3$  (MeOH: $\text{CH}_2\text{Cl}_2$ , 1:25) to afford the desired **46** (73.0 mg, 57%) as a colorless oil: IR (film,  $\text{CH}_2\text{Cl}_2$ ) 3334, 2924, 2850, 1448, 1109  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.34-7.27 (m, 5 H), 5.98 (s, 1 H), 4.79 (s, 2 H), 3.79 (s, 4 H), 3.03 (t,  $J = 6.0$  Hz, 2 H), 2.86 (t,  $J = 6.0$  Hz, 2 H), 2.55 (tt,  $J = 10.4, 4.0$  Hz, 1 H), 1.92 (d,  $J = 12.4$  Hz, 2 H), 1.84 (br s, 1 H), 1.73 (dt,  $J = 12.8, 3.6$  Hz, 2 H), 1.61 (d,  $J = 11.6$  Hz, 1 H), 1.31-1.08 (m, 5 H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  151.2, 137.33, 137.30, 128.8, 128.5, 127.5, 101.8, 68.0, 56.6, 56.4, 46.8, 44.3, 33.3, 26.1, 25.0, 20.0; HRMS (ESI)  $m/z$  calcd for  $\text{C}_{20}\text{H}_{29}\text{N}_4$  (M+H) $^+$  325.2387, found 325.2386.




*1*-((6-Benzyl-4,5,6,7-tetrahydropyrazolo[1,5-*c*]pyrimidin-2-yl)-*N*-((5-methylfuran-2-yl)methyl)methanamine **47**

Prepared according to the General Procedure 1, using 5-methylfurfurylamine (50.0  $\mu$ L, 0.435 mmol). The crude residue was purified by chromatography on basic  $\text{Al}_2\text{O}_3$  (MeOH: $\text{CH}_2\text{Cl}_2$ , 1:25) to afford the desired **47** (93.0 mg, 70%) as a colorless oil: IR (film,  $\text{CH}_2\text{Cl}_2$ ) 3334, 2924, 1493, 1450, 1342  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.35-7.29 (m, 5 H), 6.06 (d,  $J = 2.8$  Hz, 1 H), 6.00 (s, 1H), 5.87 (dd,  $J = 2.8, 0.8$  Hz, 1 H), 4.81 (s, 2 H), 3.81 (s, 2 H), 3.79 (s, 2 H), 3.77 (s, 2 H), 3.05 (t,  $J = 6.0$  Hz, 2 H), 2.88 (t,  $J = 6.0$  Hz, 2 H), 2.27 (s, 3 H), 1.85 (br s, 1 H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  151.9, 151.3, 150.7, 137.40, 137.35, 128.9, 128.5, 127.6, 107.8, 105.9, 102.0, 68.0, 56.7, 46.9, 46.3, 45.8, 20.0, 13.6; HRMS (ESI)  $m/z$  calcd for  $\text{C}_{20}\text{H}_{25}\text{N}_4\text{O}$  (M+H) $^+$  337.2023, found 337.2021.




*1*-((6-Benzyl-4,5,6,7-tetrahydropyrazolo[1,5-*c*]pyrimidin-2-yl)-*N*-((tetrahydrofuran-2-yl)methyl)methanamine **48**

Prepared according to the General Procedure 1, using tetrahydrofurylmethylamine (46.0  $\mu$ L, 0.433 mmol). The crude residue was purified by chromatography on basic  $\text{Al}_2\text{O}_3$  (MeOH: $\text{CH}_2\text{Cl}_2$ , 1:25) to afford the desired **48** (90.0 mg, 70%) as a colorless oil: IR (film,  $\text{CH}_2\text{Cl}_2$ ) 3359, 2937, 1541, 1451, 1062  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.35-7.28 (m, 5 H), 6.00 (s, 1 H), 4.79 (s, 2 H), 4.04 (ddd,  $J = 14.0, 7.0, 4.0$  Hz, 1 H), 3.86-3.79 (m, 5 H), 3.73 (q,  $J = 7.0$  Hz, 1 H), 3.04 (t,  $J = 6.0$  Hz, 2 H), 2.87 (t,  $J = 6.0$  Hz, 2 H), 2.73 (ddd,  $J = 14.0, 7.5, 4.0$  Hz, 2 H), 2.10 (br s, 1 H), 2.00-1.94 (m, 1 H), 1.90-1.83 (m, 2 H), 1.60-1.53 (m, 1 H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  150.9, 137.4, 128.9, 128.5, 127.5, 101.8, 78.3, 68.0, 67.8, 56.7, 53.8, 47.4, 46.9, 29.3, 25.7, 20.1; HRMS (ESI)  $m/z$  calcd for  $\text{C}_{19}\text{H}_{27}\text{N}_4\text{O}$  (M+H) $^+$  327.2179, found 327.2174.




*N*-((6-Benzyl-4,5,6,7-tetrahydropyrazolo[1,5-*c*]pyrimidin-2-yl)methyl)hexan-1-amine **49**

Prepared according to the General Procedure 1, using hexylamine (57.0  $\mu$ L, 0.432 mmol). The crude residue was purified by chromatography on SiO<sub>2</sub> (MeOH:CH<sub>2</sub>Cl<sub>2</sub>, 1:25, with 0.05% Et<sub>3</sub>N) to afford the desired **49** (74.6 mg, 58%) as a yellow oil: IR (film, CH<sub>2</sub>Cl<sub>2</sub>) 3346, 2924, 1716, 1493, 1364 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  7.35-7.28 (m, 5 H), 6.04 (s, 1 H), 4.80 (s, 2 H), 3.83 (s, 2 H), 3.80 (s, 2 H), 3.70 (br s, 1 H), 3.04 (t,  $J$  = 6.5 Hz, 2 H), 2.87 (t,  $J$  = 6.5 Hz, 2 H), 2.70 (t,  $J$  = 7.5 Hz, 2 H), 1.55 (p,  $J$  = 8.5 Hz, 2 H), 1.34-1.26 (m, 6 H), 0.88 (t,  $J$  = 6.5 Hz, 3 H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  149.5, 137.6, 137.3, 128.8, 128.5, 127.6, 102.2, 68.0, 56.7, 49.0, 46.8, 46.6, 31.6, 29.2, 26.9, 22.5, 20.1, 14.0; HRMS (ESI)  $m/z$  calcd for C<sub>20</sub>H<sub>31</sub>N<sub>4</sub> (M+H)<sup>+</sup> 327.2543, found 327.2542.




*tert-Butyl 4-(((6-benzyl-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidin-2-yl)methyl)amino)piperidine-1-carboxylate* **50**

Prepared according to the General Procedure 1, using 4-amino-1-Boc-piperidine (90.0 mg, 0.436 mmol). The crude residue was purified by chromatography on SiO<sub>2</sub> (MeOH:CH<sub>2</sub>Cl<sub>2</sub>, 1:20, with 0.05% Et<sub>3</sub>N) to afford the desired **50** (118 mg, 70%) as a colorless oil: IR (film, CH<sub>2</sub>Cl<sub>2</sub>) 3327, 2932, 1684, 1420, 1167, 1141 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.35-7.29 (m, 5 H), 5.98 (s, 1 H), 4.80 (s, 2 H), 4.04 (br s, 2 H), 3.81 (s, 4 H), 3.05 (t,  $J$  = 6.4 Hz, 2 H), 2.88 (t,  $J$  = 6.0 Hz, 2 H), 2.80 (t,  $J$  = 11.2 Hz, 2 H), 2.71 (tt,  $J$  = 10.4, 3.6 Hz, 1 H), 1.88 (d,  $J$  = 11.2 Hz, 2 H), 1.46 (s, 9 H), 1.36-1.26 (m, 3 H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  154.8, 150.7, 137.5, 137.3, 128.8, 128.5, 127.6, 101.8, 79.3, 68.0, 56.7, 54.4, 46.9, 44.2, 32.3, 28.4, 20.1; HRMS (ESI)  $m/z$  calcd for C<sub>24</sub>H<sub>36</sub>N<sub>2</sub>O<sub>2</sub> (M+H)<sup>+</sup> 426.2864, found 426.2864.




*N-((6-Benzyl-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidin-2-yl)methyl)-2-(1H-indol-3-yl)ethanamine* **51**

Prepared according to the General Procedure 1, using tryptamine (69.0 mg 0.430 mmol). The crude residue was purified by chromatography on SiO<sub>2</sub> (MeOH:CH<sub>2</sub>Cl<sub>2</sub>, 1:25, with 0.02% Et<sub>3</sub>N) to afford the desired **51** (0.91 g, 60%) as a yellow oil: IR (film, CH<sub>2</sub>Cl<sub>2</sub>) 3195, 2924, 1453, 1342, 1105 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  8.07 (d,  $J$  = 15.5 Hz, 1 H), 7.62 (d,  $J$  = 8.0 Hz, 1 H), 7.36-7.28 (m, 5 H), 7.19 (td,  $J$  = 8.0, 1.0 Hz, 1 H), 7.11 (td,  $J$  = 8.0, 1.0 Hz, 1 H), 7.05 (s, 1 H), 5.95 (s, 1 H), 4.78 (s, 2 H), 3.82 (s, 2 H), 3.79 (s, 2 H), 3.04-3.02 (m, 6 H), 2.85 (t,  $J$  = 6.0 Hz, 2 H), 1.83 (br s, 2 H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  150.7, 137.4, 136.4, 128.9, 128.5, 127.6, 127.5, 121.9, 119.2, 118.9, 114.0, 111.1, 101.9, 68.0, 56.7, 49.5, 47.2, 46.9, 25.7, 20.0; HRMS (ESI)  $m/z$  calcd for C<sub>24</sub>H<sub>28</sub>N<sub>5</sub> (M+H)<sup>+</sup> 386.2339, found 386.2339.




*Lithium 6-benzyl-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidine-2-carboxylate* **52**

A solution of LiOH (5.8 mL, 5.80 mmol, 1 M in H<sub>2</sub>O) was added to a solution of **11** (550 mg, 1.93 mmol) in THF (18 mL). The reaction mixture was stirred at rt for 15 h. Another portion of LiOH (500  $\mu$ L, 0.500 mmol, 1 M solution in H<sub>2</sub>O) was added and the reaction mixture was stirred at rt for 6 h, concentrated, and water was azeotropically removed with toluene to afford the desired **52** (498 mg, 98%) as a white solid: Mp 230  $^{\circ}$ C; <sup>1</sup>H NMR (400 MHz, MeOH-d<sub>4</sub>)  $\delta$  7.38-7.28 (m, 5 H), 6.44 (s, 1 H), 4.80 (s, 2 H), 3.82 (s, 2 H), 3.10 (t,  $J$  = 6.0 Hz, 2 H), 2.93 (t,  $J$  = 6.0 Hz, 2 H); <sup>13</sup>C NMR (100 MHz, MeOH-d<sub>4</sub>)  $\delta$  170.7, 150.5, 139.3, 138.7, 130.2, 129.6, 128.7, 105.6, 68.9, 57.4, 47.9, 20.8; HRMS (ESI)  $m/z$  calcd for C<sub>14</sub>H<sub>16</sub>N<sub>3</sub>O<sub>2</sub> (M-Li+2H)<sup>+</sup> 258.1237, found 258.1236.




***N,6-Dibenzyl-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidine-2-carboxamide 53***

Prepared according to General Procedure 2, using benzylamine (46  $\mu\text{L}$ , 0.42 mmol). The crude residue was purified by chromatography on  $\text{SiO}_2$  (hexanes:EtOAc, 1:1) to afford the desired **53** (56 mg, 50%) as a white solid: Mp 92-93  $^\circ\text{C}$ ; IR (film,  $\text{CH}_2\text{Cl}_2$ ) 3327, 2924, 1655, 1528, 1451  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.37-7.30 (m, 10 H), 7.11 (br s, 1 H), 6.62 (s, 1 H), 4.81 (s, 2 H), 4.61 (d,  $J = 7.6$  Hz, 2 H), 3.81 (s, 2 H), 3.11 (t,  $J = 6.0$  Hz, 2 H), 2.94 (t,  $J = 6.0$  Hz, 2 H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  162.2, 145.9, 138.5, 137.1, 128.8, 128.6, 127.9, 127.7, 127.5, 127.34, 127.26, 104.1, 68.4, 56.5, 46.7, 43.1, 19.9; HRMS (ESI)  $m/z$  calcd for  $\text{C}_{21}\text{H}_{23}\text{N}_4\text{O}$  ( $\text{M}+\text{H}$ ) $^+$  347.1866, found 347.1862.




***6-Benzyl-N-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidine-2-carboxamide 54***

Prepared according to General Procedure 2, using aniline (95  $\mu\text{L}$ , 1.0 mmol). The crude residue was purified by chromatography on  $\text{SiO}_2$  (hexanes:EtOAc, 1:1) to afford the desired **54** (95 mg, 84%) as a white solid: Mp 94-95  $^\circ\text{C}$ ; IR (film,  $\text{CH}_2\text{Cl}_2$ ) 3364, 2931, 1676, 1593, 1526, 1427, 1308  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.65 (br s, 1 H), 7.69 (d,  $J = 8.0$  Hz, 2 H), 7.70-7.34 (m, 7 H), 7.11 (t,  $J = 7.2$  Hz, 1 H), 6.69 (s, 1 H), 4.89 (s, 2 H), 3.84 (s, 2 H), 3.15 (t,  $J = 6.0$  Hz, 2 H), 2.97 (t,  $J = 6.0$  Hz, 2 H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  160.1, 146.1, 138.9, 138.1, 129.0, 128.8, 128.6, 127.8, 123.8, 119.6, 104.3, 68.4, 56.5, 46.7, 20.0; HRMS (ESI)  $m/z$  calcd for  $\text{C}_{20}\text{H}_{21}\text{N}_4\text{O}$  ( $\text{M}+\text{H}$ ) $^+$  333.1710, found 333.1712.



***6-Benzyl-N-cyclopropyl-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidine-2-carboxamide 55***


Prepared according to General Procedure 2, using cyclopropylamine (50  $\mu\text{L}$ , 0.71 mmol). The crude residue was purified by chromatography on  $\text{SiO}_2$  (hexanes:EtOAc, 1:4) to afford the desired **55** (53.5 mg, 53%) as a yellow solid: Mp 87-88  $^\circ\text{C}$ ; IR (film,  $\text{CH}_2\text{Cl}_2$ ) 3390, 2924, 1653, 1524  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.37-7.31 (m, 5 H), 6.85 (br s, 1 H), 6.59 (s, 1 H), 4.81 (s, 2 H), 3.80 (s, 2 H), 3.12 (t,  $J = 6.0$  Hz, 2 H), 2.93 (t,  $J = 6.5$  Hz, 2 H), 2.86 (app oct,  $J = 4.0$  Hz, 1 H), 0.82 (m, 2 H), 0.60 (m, 2 H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  163.6, 146.0, 138.4, 137.0, 128.8, 128.6, 127.7, 104.0, 68.3, 56.5, 46.7, 22.2, 19.9, 6.5; HRMS (ESI)  $m/z$  calcd for  $\text{C}_{17}\text{H}_{21}\text{N}_4\text{O}$  ( $\text{M}+\text{H}$ ) $^+$  297.1710, found 297.1707.



***6-Benzyl-N-((5-methylfuran-2-yl)methyl)-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidine-2-carboxamide 56***




Prepared according to General Procedure 2, using 5-methylfurfurylamine (80  $\mu$ L, 0.71 mmol). The crude residue was purified by chromatography on SiO<sub>2</sub> (hexanes:EtOAc, 1:3) to afford the desired **56** (80 mg, 67%) as a yellow oil: IR (thin film, CH<sub>2</sub>Cl<sub>2</sub>) 3334, 2924, 1659, 1527, 1196 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  7.38-7.28 (m, 5 H), 7.03 (br s, 1 H), 6.61 (s, 1 H), 6.14 (d, *J* = 3.5 Hz, 1 H), 5.88 (dd, *J* = 3.5, 1.0 Hz, 1 H), 4.83 (s, 2 H), 4.54 (d, *J* = 5.5 Hz, 2 H), 3.81 (s, 2 H), 3.11 (t, *J* = 6.0 Hz, 2 H), 2.94 (t, *J* = 6.0 Hz, 2 H), 2.65 (s, 3 H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  161.9, 151.8, 149.6, 145.8, 138.4, 137.1, 128.8, 128.6, 127.7, 108.3, 106.2, 104.1, 68.4, 56.5, 46.7, 36.2, 19.9, 13.5; HRMS (ESI) *m/z* calcd for C<sub>20</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> (M+H)<sup>+</sup> 351.1816, found 351.1818.




**6-Benzyl-N-((tetrahydrofuran-2-yl)methyl)-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidine-2-carboxamide 57**

Prepared according to General Procedure 2, using tetrahydrofurfurylamine (110  $\mu$ L, 1.06 mmol). The crude residue was purified by chromatography on SiO<sub>2</sub> (hexanes:EtOAc, 1:3) to afford the desired **57** (64 mg, 55%) as a yellow solid: Mp 76-77 °C; IR (film, CH<sub>2</sub>Cl<sub>2</sub>) 3409, 2919, 1655, 1545, 1232 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.38-7.31 (m, 5 H), 7.11 (br s, 1 H), 6.58 (s, 1 H), 4.84 (s, 2 H), 4.06-4.04 (m, 1 H), 3.89 (q, *J* = 7.6 Hz, 1 H), 3.81 (s, 2 H), 3.77 (q, *J* = 8.0 Hz, 1 H), 3.70-3.67 (m, 1 H), 3.36 (p, *J* = 6.0 Hz, 1 H), 3.10 (t, *J* = 6.0 Hz, 2 H), 2.93 (t, *J* = 5.6 Hz, 2 H), 2.04-1.96 (m, 1 H), 1.91-1.86 (m, 2 H), 1.65-1.58 (m, 1 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  162.5, 145.9, 138.3, 137.1, 128.8, 128.6, 127.7, 103.9, 77.9, 68.4, 68.2, 56.5, 46.6, 42.7, 28.7, 25.9, 19.9; HRMS (ESI) *m/z* calcd for C<sub>19</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> (M+H)<sup>+</sup> 341.1972, found 341.1972.



**6-Benzyl-N-hexyl-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidine-2-carboxamide 58**


Prepared according to General Procedure 2, using hexylamine (137  $\mu$ L, 1.03 mmol). The crude residue was purified by chromatography on SiO<sub>2</sub> (hexanes:EtOAc, 1:3) to afford the desired **58** (85 mg, 73%) as a yellow solid: Mp 83-84 °C; IR (thin film, CH<sub>2</sub>Cl<sub>2</sub>) 3346, 2919, 1655, 1547, 1235 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.39-7.29 (m, 5 H), 6.79 (t, *J* = 5.2 Hz, 1 H), 6.59 (s, 1 H), 4.83 (s, 2 H), 3.81 (s, 2 H), 3.40 (q, *J* = 6.8 Hz, 2 H), 3.11 (t, *J* = 6.4 Hz, 2 H), 2.93 (t, *J* = 6.0 Hz, 2 H), 1.58 (p, *J* = 6.8 Hz, 2 H), 1.41-1.26 (m, 6 H), 0.89 (t, *J* = 6.8 Hz, 3 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  162.2, 146.2, 138.4, 137.1, 128.8, 128.6, 127.7, 104.0, 68.3, 56.5, 46.7, 39.1, 31.5, 29.7, 26.6, 22.5, 19.9, 14.0; HRMS (ESI) *m/z* calcd for C<sub>20</sub>H<sub>29</sub>N<sub>4</sub>O (M+H)<sup>+</sup> 341.2336, found 341.2334.



**N-(2-(1H-Indol-3-yl)ethyl)-6-benzyl-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidine-2-carboxamide 59**


Prepared according to General Procedure 2, using tryptamine (166 mg, 1.03 mmol). The crude residue was purified by chromatography on SiO<sub>2</sub> (hexanes:EtOAc, 1:4) to afford the desired **59** (94 mg, 69%) as a white solid: Mp 154-155 °C; IR (film, CH<sub>2</sub>Cl<sub>2</sub>) 3284, 2919, 1647, 1551, 1530, 1455 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.07 (br s, 1 H), 7.66 (dd, *J* = 2.6, 0.4 Hz, 1 H), 7.38-7.31 (m, 5 H), 7.20 (td, *J* = 7.2, 1.2 Hz, 1 H), 7.12 (td, *J* = 7.2, 1.2 Hz, 1 H), 7.08 (d, *J* = 2.0 Hz, 1 H), 6.95 (t, *J* = 5.6 Hz, 1 H), 6.59 (s, 1 H), 4.80 (s, 2 H), 3.80 (s, 2 H), 3.77 (q, *J* = 6.8 Hz, 2 H), 3.10 (t, *J* = 6.4 Hz, 2 H), 3.07 (t, *J* = 6.8 Hz, 2 H), 2.93 (t, *J* = 6.0 Hz, 2 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  162.3, 146.1, 138.3, 137.1, 136.4, 128.8,

128.6, 127.7, 127.4, 122.1, 121.9, 119.4, 118.9, 113.3, 111.1, 103.9, 68.3, 56.5, 46.7, 39.3, 25.6, 19.9; HRMS (ESI)  $m/z$  calcd for  $C_{24}H_{25}N_5O$  (M+H)<sup>+</sup> 400.2118, found 400.2122.




**6-Benzyl-N-cyclohexyl-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidine-2-carboxamide 60**

Prepared according to General Procedure 2, using cyclohexylamine (120  $\mu$ L, 1.04 mmol). The crude residue was purified by chromatography on  $SiO_2$  (hexanes:EtOAc, 1:3) to afford the desired product **60** (53 mg, 45%) as a yellow solid: Mp 104-105  $^{\circ}C$ ; IR (thin film,  $CH_2Cl_2$ ) 3403, 2924, 1659, 1527, 1450  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  7.37-7.30 (m, 5 H), 6.68 (d,  $J = 8.4$  Hz, 1 H), 6.59 (s, 1 H), 4.84 (s, 2 H), 3.99-3.89 (m, 1 H), 3.82 (s, 2 H), 3.10 (t,  $J = 6.4$  Hz, 2 H), 2.93 (t,  $J = 6.0$  Hz, 2 H), 2.00 (dd,  $J = 12.4, 3.6$  Hz, 2 H), 1.74 (dt,  $J = 14.0, 3.6$  Hz, 2 H), 1.41 (qt,  $J = 15.2, 3.2$  Hz, 2 H), 1.29-1.15 (m, 4 H);  $^{13}C$  NMR (100 MHz,  $CDCl_3$ )  $\delta$  161.3, 146.4, 138.4, 137.1, 128.8, 128.6, 127.7, 104.0, 68.4, 56.5, 47.7, 46.7, 33.2, 25.6, 24.9, 19.9; HRMS (ESI)  $m/z$  calcd for  $C_{20}H_{27}N_4O$  (M+H)<sup>+</sup> 339.2179, found 339.2179.




**6-Benzyl-N-(thiazol-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidine-2-carboxamide 61**

Prepared according to General Procedure 2, using 2-aminothiazole (104 mg, 1.03 mmol). The crude residue was purified by chromatography on  $SiO_2$  (hexanes:EtOAc, 1:3) to afford the desired **61** (69 mg, 59%) as a white solid: Mp 138-139  $^{\circ}C$ ; IR (film,  $CH_2Cl_2$ ) 3120, 2924, 1672, 1528, 1315, 1187  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  10.09 (br s, 1H), 7.48 (d,  $J = 3.6$  Hz, 1 H), 7.41-7.32 (m, 5 H), 6.98 (d,  $J = 3.6$  Hz, 1 H), 6.72 (s, 1 H), 4.90 (s, 2 H), 3.83 (s, 2 H), 3.15 (t,  $J = 6.4$  Hz, 2 H), 2.98 (t,  $J = 6.0$  Hz, 2 H);  $^{13}C$  NMR (100 MHz,  $CDCl_3$ )  $\delta$  159.4, 157.8, 143.8, 139.2, 137.8, 136.9, 128.9, 128.7, 127.8, 113.4, 104.8, 68.6, 56.4, 46.4, 19.9; HRMS (ESI)  $m/z$  calcd for  $C_{17}H_{18}N_5OS$  (M+H)<sup>+</sup> 340.1227, found 340.1225.



**6-Benzyl-N-(naphthalen-1-yl)-4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidine-2-carboxamide 62**



Prepared according to General Procedure 2, using 1-aminonaphthalene (124 mg, 0.855 mmol). The crude residue was purified by chromatography on  $SiO_2$  (hexanes:EtOAc, 1:1) to afford the desired **62** (104 mg, 80%) as a purple solid: Mp 117-118  $^{\circ}C$ ; IR (film,  $CH_2Cl_2$ ) 3384, 2931, 1687, 1530, 1502, 1342, 1193  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  9.27 (br s, 1H), 8.28 (d,  $J = 7.6$  Hz, 1 H), 8.01 (d,  $J = 8.0$  Hz, 1 H), 7.88 (d,  $J = 7.6$  Hz, 1 H), 7.69 (d,  $J = 8.0$  Hz, 1 H), 7.57-7.51 (m, 3 H), 7.40-7.34 (m, 5 H), 6.75 (s, 1 H), 4.96 (s, 2 H), 3.88 (s, 2 H), 3.17 (t,  $J = 6.0$  Hz, 2 H), 3.00 (t,  $J = 6.0$  Hz, 2 H);  $^{13}C$  NMR (100 MHz,  $CDCl_3$ )  $\delta$  160.5, 146.2, 139.0, 137.1, 134.1, 132.5, 128.9, 128.73, 128.66, 127.8, 126.5, 126.1, 125.95, 125.85, 124.8, 120.5, 119.1, 104.4, 68.6, 56.5, 46.7, 20.0; HRMS (ESI)  $m/z$  calcd for  $C_{24}H_{23}N_4O$  (M+H)<sup>+</sup> 383.1866, found 383.1867.







**63**



*Ethyl 4,5,6,7-tetrahydropyrazolo[1,5-c]pyrimidine-2-carboxylate* **63**


To a solution of **11** (1.3 g, 4.6 mmol) in *i*-PrOH (60 mL) was added 30% Pd/C (0.32 g, 0.91 mmol) and the flask was purged three times with vacuum/H<sub>2</sub>. The mixture was stirred at 40 °C for 4 d under a H<sub>2</sub> atmosphere (balloon), then filtered through a pad of Celite, concentrated, and the crude residue was purified by chromatography on a small pad of SiO<sub>2</sub> (EtOAc, 100%) to afford the desired **63** as a colorless oil (0.42 g, 47%): IR (film) 3308, 2975, 2932, 2868, 1712, 1465, 1441, 1230, 1191, 777 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 6.49 (s, 1 H), 5.01 (s, 2 H), 4.31 (q, *J* = 7.1 Hz, 2 H), 3.14 (t, *J* = 6.1 Hz, 2 H), 2.79 (t, *J* = 6.0 Hz, 2 H), 1.32 (t, *J* = 7.1 Hz, 3 H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 162.6, 142.4, 138.5, 106.2, 63.8, 60.6, 40.9, 24.0, 14.2; HRMS (ESI) *m/z* calcd for C<sub>9</sub>H<sub>14</sub>O<sub>2</sub>N<sub>3</sub> (M+H)<sup>+</sup> 196.1081, found 196.1082.


























**29**













































43






















































































































































63





63

